Liquidia Corporation
LQDAHealthcare|Medical - Pharmaceuticals|US
$44.40
-0.09 (-0.20%)
Tangible Book / Share
$2.12
Graham Number
$8.78
Cash / Share
$3.20
About
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Stock Price
+73.4%(1Y)
1M
+58.5%
3M
-50.8%
6M
+5.0%
YTD
+28.7%
1Y
+62.9%
3Y
+583.6%
5Y
+932.6%
Pipeline Summary
11 total trials2
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
Completed: 3Active: 3Recruiting: 3Terminated: 1Not Yet Recruiting: 1
Active Trials (6)
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
NCT03992755Primary Pulmonary Hypertension
Phase 3Active
Enrollment: 92 participants
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
NCT07561034Pulmonary Hypertension
N/ARecruiting
Enrollment: 30 participants
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
NCT07759804Pulmonary Arterial Hypertension (PAH)
Phase 4Recruiting
Enrollment: 20 participants
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
NCT04691154Pulmonary Arterial Hypertension
Phase 3Active
Enrollment: 28 participants
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Phase 3Recruiting
Enrollment: 344 participants
Key Facts
Market Cap$3.97B
Employees216 (+38% YoY)
CEORoger A. Jeffs
IPO DateJul 26, 2018
Beta0.54
52-Week Range$22.31 – $93.61
Avg Volume2,879,581
ExchangeNASDAQ
Websiteliquidia.com
Ownership
Float72.9%
Shares Outstanding89.5M
Recent Insider Trades
Boyle DanaSELL
Oct 26, 20261,581 shares @ $43.19
Adair JasonSELL
Oct 26, 2026688 shares @ $43.19
Schundler RussellOPTION EX.
Oct 9, 20266,409 shares
Schundler RussellOPTION EX.
Oct 9, 20263,758 shares
Schundler RussellSELL
Oct 12, 202613,692 shares @ $28.48
Peers
Recent News
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
Nov 3, 2026 · globenewswire.com
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Oct 28, 2026 · zacks.com
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Oct 26, 2026 · zacks.com
Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments
Oct 21, 2026 · newsfilecorp.com
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Oct 14, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:20 AM